Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company, on Tuesday announced significant one-year follow-up results from its AlloStem or CELZ-201 Type 2 Diabetes pilot study.
The study demonstrated that CELZ-201, a proprietary allogeneic cell line, achieved an 80 percent overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels in late-stage Type 2 Diabetes patients, with no serious adverse effects observed.
The trial, which included 20 patients, validated the safety and effectiveness of CELZ-201 and mirrored the infusion procedure used in the company's FDA-cleared Type 1 Diabetes clinical trial.
The promising results represent a potential breakthrough in diabetes care, especially for patients who may not benefit from autologous therapies.
Creative Medical Technology is now preparing to advance the development of CELZ-201 for late-stage Type 2 Diabetes treatment and is also exploring other therapeutic applications for this innovative cell-based therapy.
With the success of this study, the company is poised to expand its portfolio of regenerative therapies, which includes additional treatments for early-stage Type 1 Diabetes and brittle Type 1 Diabetes, positioning Creative Medical Technology to transform patient care in endocrinology.
Currently, CELZ is trading at $3.87 down by 2.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.